Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

摘要: Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy slowing progression disease. This review focusses on that can affect B-cell biology may utility disease management. The risk genes for MS are examined from drug target perspective. Existing therapies with actions together new development described. potential experimental molecules effects also considered. Small diverse be cytotoxic, anti-inflammatory anti-viral. current cell-directed often kill subsets, which effective but lead side toxicity. A deeper understanding effect should better selectivity, efficacy, improved safety profile. Small-molecule drugs, once patent term has expired, provide uniquely sustainable form healthcare.